IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors sponsored by NCI September 24, 2024
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors September 18, 2024
ArsenalBio Announces $325 Million Financing to Advance Programmable Cell Therapy Programs in solid tumors through Clinical Development September 10, 2024
NextPoint Therapeutics Announces First-in-class T Cell Engager NPX372 As New Drug Candidate Targeting B7-H7 in Solid Tumors September 10, 2024
FAILED TRIAL: PRECISION1 trial of nab-sirolimus in patients with solid tumors with TSC1/2 inactivating mutations to be halted as study unlikely to exceed the efficacy threshold August 27, 2024
First patient dosed in trial of MOMA-313 in patients with cancers carrying mutations in DNA repair genes August 27, 2024
Enrollment Completed in China GC/GEJ Pivotal Ph 2 Clinical Trial of Claudin18.2 CAR T (Satri-cel) August 27, 2024
Ph 1a/1b trial of OMX-040 in patients with advanced solid tumors advanced to expansion phase in kidney cancer and angiosarcoma August 27, 2024
First Solid Tumor Patient Treated with Second, Higher Dose in Ph 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease August 27, 2024
Human Research Ethics Committee (HREC) in Australia clears initiation of Ph 1 trial of MNPR-101-Lu August 27, 2024
Enrollment on track in Ph 2 part of PYNNACLE trial of rezatapopt monotherapy in TP53 Y220C & KRAS WT advanced solid tumor patients August 22, 2024
Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from Ph 2 SPARTA Trial Announced August 22, 2024
FDA granted Fast Track designation to Deltacel™ (KB-GDT-01) Gamma Delta T-cell (GDT) therapy August 22, 2024
Initial Data from Ph 1 Clinical Trial of EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2 announced August 13, 2024
